Literature DB >> 28553835

Pharmacological Manipulation of Cortical Inhibition in the Dorsolateral Prefrontal Cortex.

Bahar Salavati1,2,3,4, Tarek K Rajji1,2,3,4, Reza Zomorrodi1,2,3,4, Daniel M Blumberger1,2,3,4, Robert Chen5, Bruce G Pollock1,2,3, Zafiris J Daskalakis1,2,3,4.   

Abstract

Cortical inhibition (CI) occurs largely through GABA receptor-mediated inhibitory neurotransmission, which can be modulated by cholinergic, dopaminergic, and glutamatergic inputs. Transcranial magnetic stimulation (TMS) can be used to index CI through a paradigm known as long-interval CI (LICI). When TMS is combined with electroencephalography (EEG), LICI can index GABA receptor-mediated inhibitory neurotransmission in the dorsolateral prefrontal cortex (DLPFC). We conducted a hypothesis-driven pharmacological study to assess the role of cholinergic, dopaminergic, GABAergic, and glutamatergic neurotransmission on LICI from the DLPFC using TMS-EEG. In this randomized controlled, double-blind crossover within-subject study, 12 healthy participants received five sessions of LICI to the DLPFC in a random order, each preceded by the administration of placebo or one of the four active drugs. LICI was assessed after each drug administration and compared to LICI after placebo. Relative to placebo, baclofen resulted in a significant increase in LICI, while rivastigmine resulted in a significant decrease in LICI. Dextromethorphan and L-DOPA did not result in a significant change in LICI relative to placebo. Our study confirms that LICI in the DLPFC is largely mediated by GABAB receptor-mediated inhibitory neurotransmission and also suggests that cholinergic modulation decreases LICI in the DLPFC. Such findings may help guide future work examining the neurophysiological impact of these neurotransmitters in healthy and diseased states.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28553835      PMCID: PMC5729552          DOI: 10.1038/npp.2017.104

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  55 in total

1.  Interactions between two different inhibitory systems in the human motor cortex.

Authors:  T D Sanger; R R Garg; R Chen
Journal:  J Physiol       Date:  2001-01-15       Impact factor: 5.182

Review 2.  Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

Authors:  R J Polinsky
Journal:  Clin Ther       Date:  1998 Jul-Aug       Impact factor: 3.393

3.  Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs.

Authors:  U Ziemann; F Tergau; D Bruns; J Baudewig; W Paulus
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1997-12

4.  Dopamine increases inhibition in the monkey dorsolateral prefrontal cortex through cell type-specific modulation of interneurons.

Authors:  Sven Kröner; Leonid S Krimer; David A Lewis; Germán Barrionuevo
Journal:  Cereb Cortex       Date:  2006-06-13       Impact factor: 5.357

5.  Nicotinic and muscarinic modulations of excitatory synaptic transmission in the rat prefrontal cortex in vitro.

Authors:  C Vidal; J P Changeux
Journal:  Neuroscience       Date:  1993-09       Impact factor: 3.590

6.  Dopamine innervation of a subclass of local circuit neurons in monkey prefrontal cortex: ultrastructural analysis of tyrosine hydroxylase and parvalbumin immunoreactive structures.

Authors:  S R Sesack; V A Hawrylak; D S Melchitzky; D A Lewis
Journal:  Cereb Cortex       Date:  1998 Oct-Nov       Impact factor: 5.357

7.  Presynaptic GABAB receptors modulate thalamic excitation of inhibitory and excitatory neurons in the mouse barrel cortex.

Authors:  James T Porter; Dalila Nieves
Journal:  J Neurophysiol       Date:  2004-07-14       Impact factor: 2.714

Review 8.  Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders.

Authors:  Yukiori Goto; Charles R Yang; Satoru Otani
Journal:  Biol Psychiatry       Date:  2009-10-14       Impact factor: 13.382

9.  Characterization of GABAB-receptor mediated neurotransmission in the human cortex by paired-pulse TMS-EEG.

Authors:  Isabella Premoli; Davide Rivolta; Svenja Espenhahn; Nazareth Castellanos; Paolo Belardinelli; Ulf Ziemann; Florian Müller-Dahlhaus
Journal:  Neuroimage       Date:  2014-09-19       Impact factor: 6.556

10.  Evidence for pretreatment LICI deficits among depressed children and adolescents with nonresponse to fluoxetine.

Authors:  Paul E Croarkin; Paul A Nakonezny; Mustafa M Husain; John D Port; Tabatha Melton; Betsy D Kennard; Graham J Emslie; F Andrew Kozel; Zafiris J Daskalakis
Journal:  Brain Stimul       Date:  2013-12-03       Impact factor: 8.955

View more
  4 in total

1.  Pharmacological mechanisms of interhemispheric signal propagation: a TMS-EEG study.

Authors:  Jeanette Hui; Reza Zomorrodi; Pantelis Lioumis; Bahar Salavati; Tarek K Rajji; Robert Chen; Daniel M Blumberger; Zafiris J Daskalakis
Journal:  Neuropsychopharmacology       Date:  2019-07-29       Impact factor: 7.853

2.  Maturation changes the excitability and effective connectivity of the frontal lobe: A developmental TMS-EEG study.

Authors:  Sara Määttä; Laura Säisänen; Elisa Kallioniemi; Timo A Lakka; Niina Lintu; Eero A Haapala; Päivi Koskenkorva; Eini Niskanen; Florinda Ferreri; Mervi Könönen
Journal:  Hum Brain Mapp       Date:  2019-01-15       Impact factor: 5.038

3.  Fatigue-related group III/IV muscle afferent feedback facilitates intracortical inhibition during locomotor exercise.

Authors:  Simranjit K Sidhu; Joshua C Weavil; Taylor S Thurston; Dorothea Rosenberger; Jacob E Jessop; Eivind Wang; Russell S Richardson; Chris J McNeil; Markus Amann
Journal:  J Physiol       Date:  2018-09-03       Impact factor: 5.182

4.  Pharmacological Modulation of Long-Term Potentiation-Like Activity in the Dorsolateral Prefrontal Cortex.

Authors:  Bahar Salavati; Zafiris J Daskalakis; Reza Zomorrodi; Daniel M Blumberger; Robert Chen; Bruce G Pollock; Tarek K Rajji
Journal:  Front Hum Neurosci       Date:  2018-04-24       Impact factor: 3.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.